XERS Xeris Biopharma: Company Short-Term Debts

Public company logo of Xeris Biopharma (XERS)

Xeris Biopharma (XERS) is implementing AI monitoring and XeriSol automation to refine drug production by eliminating routine labor. Scaling sales and cost reductions are delivering results, with the indicator standing at 0.00. The market trend for individual short-term debt clearly illustrates the issuer's financial health. Xeris Biopharma (XERS) is valued as a lifesaver for patients with orphan diseases due to its safe liquid drug formulations for home use.

XERS (Xeris Biopharma Holdings) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Metric breakdowns and analytics for Xeris Pharma (XERS)

- stock price and consensus target price:
Stock Price Xeris Biopharma Holdings|XERS - Consensus Target
- company stock capitalization data:
Market Capitalization Xeris Biopharma Holdings|XERS - Company Buyout Price
- business book valuation details:
Book Value per Share Xeris Biopharma|XERS - Book Capitalization|Market Value to Book Value Ratio xerispharma.com|XERS - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Xeris Biopharma|XERS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Xeris Biopharma|XERS - Company Aggregate Indebtedness|Debts to Book Capitalization Xeris Biopharma Holdings|XERS - Long-Term Debt|Company Short-Term Debts Xeris Biopharma|Quick Liquidity Indicator xerispharma.com
- net income and valuation multiples indicators:
XERS - Final Profit
Summary company analysis:Xeris Biopharma Holdings (XERS)
Manufactured products of xerispharma.com

Investors are assessing the financial stability of Xeris Biopharma (XERS) through the lens of its ability to service current liabilities. This metric aggregates the total amount of loans and notes with a maturity of less than one year. By analyzing the level of short-term obligations, one can determine the pace of debt reduction and the risk of a liquidity shortfall. For this developer of innovative injectable solutions, low debt confirms business autonomy, ensuring the seamless implementation of breakthrough technologies without reliance on external financing.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts bridgebio.com|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt COGT (Cogent Biosciences Inc)|Company Short-Term Debts KROS (Keros Pharma)|Short-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Current Liabilities|Current Liabilities KMDA|FULC: Company Short-Term Debts|Short-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Short-Term Debts|Company Short-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Current Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Rein Therapeutics RNTX|GELS (Gelteq Ltd) - Current Liabilities|Aytu Therapeutics - Company Short-Term Debts|Company Short-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)